Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance.
Wang
Hongwei
H
Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida, Tampa, FL, USA.
Cheng
Fengdong
F
Cuenca
Alex
A
Horna
Pedro
P
Zheng
Zheng
Z
Bhalla
Kapil
K
Sotomayor
Eduardo M
EM
D000595:Amino Acid Sequence; D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001549:Benzamides; D001854:Bone Marrow Cells / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology; D000068877:Imatinib Mesylate; D007108:Immune Tolerance / Q000187:drug effects / Q000276:immunology*; D008223:Lymphoma / Q000276:immunology*; D008264:Macrophages / Q000187:drug effects / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology*; D010047:Ovalbumin / Q000737:chemistry / Q000276:immunology; D010446:Peptide Fragments / Q000737:chemistry / Q000276:immunology; D010879:Piperazines / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*
D000970:Antineoplastic Agents; D001549:Benzamides; D010446:Peptide Fragments; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D010047:Ovalbumin